SGN-BB228

N/A

Report date: 2025/12/18 20:00:07

Base Information

Drug NameSGN-BB228
Drug Alias NameSGN-BB228PF-08046049BB-228PRS-346
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionTumor necrosis factor receptor superfamily member 9 agonistsAnti-MelanotransferrinAntibody-dependent cell-mediated cytotoxicity (ADCC) effects +[4] 
TargetsTumor necrosis factor receptor superfamily member 9Melanotransferrin
Therapy Area/IndicationsSkin MelanomaSolid tumoursCarcinoma, Non-Small-Cell Lung +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesGermany +[6] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesPieris Pharmaceuticals
China Registration ClassN/A

Develop Information

Active CompaniesSeagen Inc
Inactive CompaniesPfizer Inc
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsSkin MelanomaSolid tumoursPancreatic Neoplasms +[6] 

Other Information

ATC CodeN/A
Related LinksN/A